Showing promise in the landscape of obesity management, retatrutide represents a distinct approach. Different from many current medications, retatrutide works as a double agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The dual engagement encourages multiple ben… Read More